Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patientsWon Young Tak, Masatoshi Kudo, Takuji Okusaka et al.|Investigational New Drugs|2018Cited by 49
Effect of zinc supplementation in patients with type C liver cirrhosisKazuhiro Katayama, Toshifumi Ito, Mitsuru Sakakibara et al.|Open Journal of Gastroenterology|2011Cited by 13